Philadelphia, PA
Stem Cell Therapy clinics in Philadelphia
Philadelphia supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Penn Medicine, Jefferson Health, and Children's Hospital of Philadelphia, and stem cell practice in the area spans Rittenhouse, University City, and Center City. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Pennsylvania regulates physician practice through the State Board of Medicine. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Academic research at Penn Medicine and CHOP anchors the region's trial activity. The 8 Philadelphia clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Pennsylvania State Board of Medicine licensure checks.
Philadelphia Peptide Testosterone Replacement Therapy Group
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
- Stem Cell Therapy
Meeting Point Health
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Peptide Therapy
Dr. Stephen Matta DO MBA ~ Regenerative Medicine
- PRP Therapy
- Ozone Therapy
- IV Therapy
- IV Hydration
- Arthritis Treatment
Regulatory context
A note on Pennsylvania's stem cell therapy rules.
Pennsylvania cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Pennsylvania for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. The state hosts substantial academic regenerative research at Penn, Pitt, and CHOP.
-
Pennsylvania Medical Practice Act, 63 PS Section 422.1 et seq
Establishes MD licensure and discipline through the Pennsylvania State Board of Medicine. -
Pennsylvania Osteopathic Medical Practice Act, 63 PS Section 271.1 et seq
Establishes DO licensure and discipline through the Pennsylvania State Board of Osteopathic Medicine. -
Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 PS Section 201-1 et seq
Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims against providers making unsupported clinical claims.
The FDA has issued warning letters to Pennsylvania clinics offering stem cell and exosome therapies. The Pennsylvania State Boards of Medicine and Osteopathic Medicine have disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Pennsylvania Attorney General has used the Unfair Trade Practices and Consumer Protection Law to pursue providers making unsupported clinical claims. Penn, Pitt, and CHOP operate compliant IND-based regenerative research programs. Federal warning letters apply nationally.